An agonist anti-CD40 with enhanced binding to FcγRIIB showed early promise in a small cohort of patients with metastatic melanoma. Read our digest here 👉 bit.ly/4nc91nR  @juanosoriomd.bsky.social‬  @mskcancercenter.bsky.social‬

Thrilled to share our new publication on the first-in-human phase 1 trial of intratumoral Fc-engineered CD40 agonistic antibody 2141-V11 in metastatic cancer. Over 10 years of preclinical work at the Ravetch lab led to this moment, made possible by an amazing team! 🧵 🪡 www.cell.com/cancer-cell/...

Anti-CD47/CD40 antibodies are emerging as new IO treatment options! Explore recent updates on these antibodies with an expert presentation from a former SITC abstract presenter @juanosoriomd.bsky.social at the 29th JACI Annual Meeting July 24-26 in Japan or virtual: ow.ly/O36B50W0cVS 🧪 #OncSky

Join us at #CICON25, September 10-12 in Utrecht. This is an exciting venue to explore how novel insights in immuno-oncology can translate into life-changing outcomes! Review the program, submit an abstract and register today: bit.ly/4cjiDJ4 cancerimmunotherapyconference.org

Biologics and T-cell Engagers: Researchers shared updates on cutting-edge immunotherapies during this #AACR25 Clinical Trials Plenary Session. Read a recap in AACR Annual Meeting News: www.aacrmeetingnews.org/news/cutting... @juanosoriomd.bsky.social

Excited for tomorrow! 👇 #AACR25

Interested in assessing antibody-dependent cellular phagocytosis by primary macrophages? Here is a practical and optimized protocol developed by dedicated and talented members of the lab, enjoy! www.sciencedirect.com/science/arti...

Interested in myeloid cell anti-tumor immunity? I’ll be presenting at the NIH/NCI Rising Scholars Seminar Series on 17 Apr our work on Fc-optimized CD40 Agonistic Antibody and TLS formation and induction of Systemic Antitumor Immunity urldefense.com/v3/__https:/...

Thrilled to present at @theaacr.bsky.social annual meeting at the Clinical Trials Plenary Session on Biologics and T-cell Engagers! See you there to present some exciting data on our Fc-engineered CD40 agonistic antibody #AACR25

Betty Kim & Wen Jiang and colleagues report the design and characterization of an antibody–toxin conjugate targeting CD47, promoting anti-tumor immunity in preclinical cancer models. @bettykimmdphd.bsky.social @wenjiang-nano.bsky.social @mdanderson.bsky.social ⬇️ www.nature.com/articles/s43...

New Perspective article from Scott McConnell & @acasadevall1.bsky.social @johnshopkinssph.bsky.social highlights the importance of constant regions in influencing the specificity and functionality of #antibodies #immunology #immunosky

Curious if people are starting to receive NOAs more recently? Whether any signs of normalcy or whether the waiting still continues? Are these categories 1-4 now in action?

Science not silence

So needed at this moment

1. UPDATE The NIH is still blocking most ongoing scientific funding over concerns about DEI, according to NIH sources and internal NIH correspondence. The freeze has continued even after top NIH officials acknowledged that continuing to block the funding would violate a federal court order.

🎥 @juanosoriomd.bsky.social discusses a Phase I study on 2141-V11, an anti-CD40 antibody designed to enhance FcγRIIB binding, aiming to improve tumor response & reduce toxicity: ➡️ https://buff.ly/3BCEtJL ⬅️ @sitcancer.bsky.social #SITC24 #Immunotherapy

Thrilled to present our for on this co-“stimulating” session organized by @sitcancer.bsky.social Join us this Thursday! Moderated by leaders in the field and presentations of exciting progress in IO for cancer. sitcancer.org/education/we...

Taking a deep breath, hoping this is a brighter sky